Movement Alert｜BIOCYTOGEN-B Falls 6.95% in Regular Trading, Biotechnology Sector Weakens Broadly

Market Focus10-08

On October 8, BIOCYTOGEN-B fell 6.95% in regular trading, trading at HK$72.1/share, with Turnover of HK$141 million.

The decline came amid broad-based weakness in Hong Kong-listed biotechnology stocks. Within the sector, Akeso fell 2.11%, Innovent Bio fell 3.03%, BeOne Medicines fell 1.01%, 3SBio fell 3.76%, and CanSino Biologics fell 2.53%. The company is scheduled to disclose its first three quarters results on October 30, and some funds chose to take profits ahead of the announcement.

BIOCYTOGEN-B is a China-based company that provides innovative model animals and preclinical pharmaceutical research services based on its proprietary gene editing technology. The company utilizes its self-developed RenMice fully human antibody platform for antibody drug development, with businesses covering model animal sales, preclinical pharmacology and efficacy evaluation, and antibody development.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment